Objective: To critically review the body of clinical trials refuting or supporting the efficacy of topical antihistamines in the relief of pruritus.
Design: Review of PubMed from January 1950 through September 2009 and the Cochrane Database of Systematic Reviews to identify therapeutic trials of topical antihistamines in the relief of pruritus.
Main Outcome Measures: All randomized controlled trials or clinical trials of topical antihistaminic compounds used in the treatment of pruritus. The authors found 19 trials throughout the literature. The quality of each trial was ranked by applying a modified version of Sackett's criteria for clinical evidence. Grade A trials are large, randomized, double-blind, placebo-controlled studies with low false-positive (alpha) and low false-negative (beta) errors. Grade B studies are also randomized, double-blind, placebo-controlled studies, but include a small number of patients. Grade C trials lack one or more of the following criteria: randomization, placebo control or blinding.
Results: Only four large, randomized, double-blind, placebo-controlled clinical trials with definitive conclusions (grade A) support the use of topical antihistaminic agents, specifically topical doxepin, for relief of pruritus. Of seven grade B trials, four supported the efficacy of topical antihistamines while three refute their use in relieving pruritus. One grade B trial was inconclusive. All remaining trials (grade C) lacked placebo controls or randomization, or contained fewer than 20 patients in each treatment group.
Conclusion: While topical antihistamines are widely prescribed for the treatment of pruritus, the evidence to support their use is mixed. Topical doxepin has been demonstrated to reduce pruritus. Evidence is lacking, however, for other topical antihistamines, including diphenhydramine (Benadryl), that are widely used and available without a prescription.
Download full-text PDF |
Source |
---|
Clin Transl Allergy
January 2025
Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Background: Seasonal allergic rhinitis (AR) impacts public health by affecting work productivity and quality of life. The Swedish tree pollen season starts in February with alder and hazel pollination, followed by birch and ends with oak in May. Systemic corticosteroids are often prescribed when topical treatments fail, despite limited evidence supporting their efficacy.
View Article and Find Full Text PDFSymmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a rare, symmetrical skin eruption triggered by various medications, predominantly beta-lactam antibiotics. We report the case of a 69-year-old male with moderate-to-severe ulcerative colitis who developed SDRIFE following the seventh intravenous administration of infliximab. The patient presented with symmetrical, pruritic erythema in the cubital and popliteal fossae, groins, gluteal and retroauricular regions without systemic involvement.
View Article and Find Full Text PDFMymensingh Med J
January 2025
Dr Halima Begum, Associate Professor, Department of Pharmacology, Enam Medical College and Hospital (EMCH), Dhaka, Bangladesh; E-mail:
Now-a-days, all over the world, skin disease are the fourth most common cause of disability. A significant amount of patient attending the dermatology outdoor of any major hospital in a daily basis. Irrational drug prescribing is a common contemplation in clinical practice.
View Article and Find Full Text PDFAesthet Surg J
December 2024
Division of Plastic and Reconstructive Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Background: Skin adhesives containing 2-ocyl cyanoacrylate are a common source of allergic contact dermatitis (ACD) that complicate postoperative wound healing. There are limited studies that describe postoperative cutaneous reactions to skin adhesives and clinical management.
Objectives: To review the incidence, description, and clinical management of surgical site ACD to 2-ocyl cyanoacrylate.
World Allergy Organ J
December 2024
National Allergy Council, Sydney NSW, 2000, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!